NervGen Pharma Corp.
NGENF
$4.43
$0.204.78%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.76% | 26.15% | -2.49% | -6.75% | -1.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.50% | 34.08% | 40.28% | 38.46% | 16.25% |
| Operating Income | -7.50% | -34.08% | -40.28% | -38.46% | -16.25% |
| Income Before Tax | -4.69% | -13.94% | -24.85% | -5.61% | -20.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.69% | -13.94% | -24.85% | -5.61% | -20.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.69% | -13.94% | -24.85% | -5.61% | -20.93% |
| EBIT | -7.50% | -34.08% | -40.28% | -38.46% | -16.25% |
| EBITDA | -7.65% | -34.53% | -40.95% | -38.95% | -16.67% |
| EPS Basic | 4.74% | -1.00% | -6.02% | 8.99% | -10.06% |
| Normalized Basic EPS | 4.70% | -1.00% | -5.98% | 9.00% | -10.16% |
| EPS Diluted | 4.74% | -1.00% | -6.02% | 8.99% | -10.06% |
| Normalized Diluted EPS | 4.70% | -1.00% | -5.98% | 9.00% | -10.16% |
| Average Basic Shares Outstanding | 10.00% | 13.47% | 17.73% | 13.94% | 9.91% |
| Average Diluted Shares Outstanding | 10.00% | 13.47% | 17.73% | 13.94% | 9.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |